Status:
public
Videos: (
0
) Documents: (
0
) Comments: (
0
)
Group description
Monoclonal cells are defined as a group of cells produced from a single ancestral cell by repeated cellular replication. Thus they can be said to form a single "clone".
Group Videos
No videos have been added jet. You may join this group and add yours now.
Group Documents
No documents have been added jet. You may join this group and add yours now.
More on Sciencestage
- Rebuilding Iraq s Mental Health Care System - medicine, mental ...
June 29, 2007 presentation by Keith Humphreys for the Stanford School of Medicine Medcast lecture series. Keith Humphreys, professor of psychiatry and behavioral science at ... - Mexican Migrant Health - international, public, health, migrant ...
October 18, 2007 presentation by Enrique Rios Espinosa for the Stanford School of Medicine Medcast lecture series. Dr. Enrique Rios Espinosa, Deputy Director for Migrant Health ... - The latest releases in Medicine Medicine
sciencestage.com ScienceStage.com is a virtual conference room, lecture hall, laboratory, library and meeting venue all in one.
News
- Human monoclonal antibody firm collaborating with Big Pharma
Immunome, which has developed a way to clone monoclonal human antibodies that can be used to help develop more effective cancer drugs and with potential applications for rare diseases, has signed its first research and development partnership with a Big Pharma company. The Wynnewood, Pennsylvania company’s approach differs from its competitors, says Timothy Pelura, the CEO. [...] - Peregrine to Present at BIO CEO and Investor Conference on Tuesday, February 14, 2012 at 8:30 AM EST
TUSTIN, CA-- - Peregrine Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, today announced ... - IMMUNE Pharmaceuticals Granted US$1 Million (NIS 3.8M) by the Office of the Chief Scientist in Israel
HERZLIYA, Israel and NEW YORK -- IMMUNE Pharmaceuticals, an emerging leader in the development of monoclonal antibody based therapeutics for the treatment of inflammatory diseases and cancer, today announced ... - Compugen Cancer Target Results Demonstrate Significant Potential for Cancer Immunotherapy
Compugen Ltd. announced today results demonstrating the therapeutic potential of CGEN-15001T as a drug target for treatment of multiple cancers by means of monoclonal antibody therapy. - Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast: 2011-2016
NEW YORK, Feb. 7, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast: 2011-2016 ... - Immunomedics Awarded Broad Patent for Anti-CD20 and Anti-CD22 Combination Therapy
MORRIS PLAINS, N.J. -- Immunomedics, Inc. , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other ... - Immunomedics Announces Second Quarter Fiscal 2012 Results and Clinical Program Developments
MORRIS PLAINS, N.J. -- Immunomedics, Inc. , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other ... - Compugen reports cancer treatment potential for CGEN-1500IT protein
The company's CGEN-15001T protein has demonstrated therapeutic potential of a drug target for treatment of multiple cancers by means of monoclonal antibody therapy. - Drug Delivery Products Market
NEW YORK, Jan. 31, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Drug Delivery Products Market http://www.reportlinker.com/p0765799/Drug-Delivery-Products-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_TechnologyUS ... - InflaRx Announces Successful Conduct of Its Clinical Phase I Trial with IFX-1, a New Monoclonal Antibody Inhibiting ...
InflaRx announced today the successful completion of its recent clinical phase I study investigating its lead drug candidate IFX-1, a new first in class monoclonal antibody inhibiting complement driven inflammation.
Related on Wikipedia
- Monoclonal antibodies - Wikipedia, the free encyclopedia
Monoclonal antibodies (mAb or moAb) are monospecific antibodies that are the same because they are made by identical immune cells that are all clones of a unique parent cell. - Monoclonal gammopathy - Wikipedia, the free encyclopedia
Main page; Contents; Featured content; Current events; Random article; Donate to Wikipedia - Monoclonal antibody therapy - Wikipedia, the free encyclopedia
Monoclonal antibody therapy is the use of monoclonal antibodies (or mAb) to specifically bind to target cells or proteins. This may then stimulate the patient's immune system ... - Monoclonal gammopathy of undetermined significance - Wikipedia ...
Monoclonal gammopathy of undetermined significance (MGUS, unknown or uncertain may be substituted for undetermined), formerly benign monoclonal gammopathy, is a condition in ... - List of monoclonal antibodies - Wikipedia, the free encyclopedia
This is a list of therapeutic, diagnostic and preventive monoclonal antibodies, antibodies which are clones of a single parent cell. When used as drugs, the International ... - Paraproteinemia - Wikipedia, the free encyclopedia
Paraproteinemia, or monoclonal gammopathy, is the presence of excessive amounts of a single monoclonal gammaglobulin (in this case denominated "paraprotein") in the blood. - Ki-67 (protein) - Wikipedia, the free encyclopedia
Antigen KI-67 also known as Ki-67 or MKI67 is a protein that in humans is encoded by the MKI67 gene (antigen identified by monoclonal antibody Ki-67). - Trehalose - Wikipedia, the free encyclopedia
Trehalose, also known as mycose or tremalose, is a natural alpha-linked disaccharide formed by an α,α-1,1-glucoside bond between two α-glucose units. - Centocor - Wikipedia, the free encyclopedia
Janssen Biotech, Inc., formerly Centocor Biotech, Inc., is a biotechnology company that was founded in Philadelphia in 1979 with an initial goal of developing new diagnostic ... - Trastuzumab - Wikipedia, the free encyclopedia
Trastuzumab (INN; trade name Herceptin) is a monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat certain breast cancers.